메뉴 건너뛰기




Volumn 4, Issue 6 SPEC. ISS., 2005, Pages 16-23

Testosterone substitution and the prostate

Author keywords

Benign prostatic hyperplasia; Hypogonadism; Lower urinary tract symptoms; Prostate; Prostate cancer; Prostate specific antigen; Testosterone substitution; Testosterone therapy

Indexed keywords

ANDROGEN; FINASTERIDE; TESTOSTERONE;

EID: 20544450734     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.05.004     Document Type: Conference Paper
Times cited : (4)

References (36)
  • 1
    • 0036613016 scopus 로고    scopus 로고
    • Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of the International Society for the Study of the Aging Male (ISSAM)
    • A. Morales, and B. Lunenfeld Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of The International Society for the Study of the Aging Male (ISSAM) Aging Male 5 2002 74 86
    • (2002) Aging Male , vol.5 , pp. 74-86
    • Morales, A.1    Lunenfeld, B.2
  • 2
    • 0036858514 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update
    • AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002;8:439-56.
    • (2002) Endocr Pract , vol.8 , pp. 439-456
  • 3
    • 1642458222 scopus 로고    scopus 로고
    • Risks of testosterone-replacement therapy and recommendations for monitoring
    • E.L. Rhoden, and A. Morgentaler Risks of testosterone-replacement therapy and recommendations for monitoring N Engl J Med 350 2004 482 492
    • (2004) N Engl J Med , vol.350 , pp. 482-492
    • Rhoden, E.L.1    Morgentaler, A.2
  • 4
    • 0036487661 scopus 로고    scopus 로고
    • Androgen replacement therapy and prostate safety
    • A. Morales Androgen replacement therapy and prostate safety Eur Urol 41 2002 113 120
    • (2002) Eur Urol , vol.41 , pp. 113-120
    • Morales, A.1
  • 5
    • 0032870080 scopus 로고    scopus 로고
    • Risks versus benefits of testosterone therapy in elderly men
    • S. Basaria, and A.S. Dobs Risks versus benefits of testosterone therapy in elderly men Drugs & Aging 15 1999 131 142
    • (1999) Drugs & Aging , vol.15 , pp. 131-142
    • Basaria, S.1    Dobs, A.S.2
  • 6
    • 0030640841 scopus 로고    scopus 로고
    • Clinical review 85: Emerging issues in androgen replacement therapy
    • S. Bhasin, and W.J. Bremner Clinical review 85: Emerging issues in androgen replacement therapy J Clin Endocrinol Metab 82 1997 3 8
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 3-8
    • Bhasin, S.1    Bremner, W.J.2
  • 7
    • 20544451937 scopus 로고    scopus 로고
    • Testosterone and the prostate
    • E. Nieschlag H.M. Behre 3rd ed. Cambridge University Press
    • J.T. Isaacs Testosterone and the prostate E. Nieschlag H.M. Behre Testosterone: action, deficiency, substitution 3rd ed. 2004 Cambridge University Press 347 374
    • (2004) Testosterone: Action, Deficiency, Substitution , pp. 347-374
    • Isaacs, J.T.1
  • 8
    • 0036636871 scopus 로고    scopus 로고
    • Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. [Reprint of historical article.]
    • C. Huggins, and C.V. Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. [Reprint of historical article.] J Urol 168 2002 9 12
    • (2002) J Urol , vol.168 , pp. 9-12
    • Huggins, C.1    Hodges, C.V.2
  • 10
    • 0021149603 scopus 로고
    • The development of human benign prostatic hyperplasia with age
    • S.J. Berry, D.S. Coffey, P.C. Walsh, and L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474 479
    • (1984) J Urol , vol.132 , pp. 474-479
    • Berry, S.J.1    Coffey, D.S.2    Walsh, P.C.3    Ewing, L.L.4
  • 11
    • 0025884064 scopus 로고
    • Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study
    • A. Gray, H.A. Feldman, J.B. McKinlay, and C. Longcope Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study J Clin Endocrinol Metab 73 1991 1016 1025
    • (1991) J Clin Endocrinol Metab , vol.73 , pp. 1016-1025
    • Gray, A.1    Feldman, H.A.2    McKinlay, J.B.3    Longcope, C.4
  • 13
    • 0028358995 scopus 로고
    • Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls
    • H.M. Behre, J. Bohmeyer, and E. Nieschlag Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls Clin Endocrinol (Oxf) 40 1994 341 349
    • (1994) Clin Endocrinol (Oxf) , vol.40 , pp. 341-349
    • Behre, H.M.1    Bohmeyer, J.2    Nieschlag, E.3
  • 15
    • 0343048346 scopus 로고    scopus 로고
    • Endocrine status in elderly men with lower urinary tract symptoms: Correlation of age, hormonal status, and lower urinary tract function
    • G. Schatzl, C. Brossner, S. Schmid, W. Kugler, M. Roehrich, and T. Treu Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function Urology 55 2000 397 402
    • (2000) Urology , vol.55 , pp. 397-402
    • Schatzl, G.1    Brossner, C.2    Schmid, S.3    Kugler, W.4    Roehrich, M.5    Treu, T.6
  • 16
    • 0037241073 scopus 로고    scopus 로고
    • 5 alpha-reductase inhibitors: What's new?
    • C.L. Foley, and R.S. Kirby 5 alpha-reductase inhibitors: what's new? Curr Opin Urol 13 2003 31 37
    • (2003) Curr Opin Urol , vol.13 , pp. 31-37
    • Foley, C.L.1    Kirby, R.S.2
  • 18
    • 2442543161 scopus 로고    scopus 로고
    • Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men
    • C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A.M. Matsumoto, and P.J. Snyder Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men J Clin Endocrinol Metab 89 2004 2085 2098
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2085-2098
    • Wang, C.1    Cunningham, G.2    Dobs, A.3    Iranmanesh, A.4    Matsumoto, A.M.5    Snyder, P.J.6
  • 19
    • 0030694397 scopus 로고    scopus 로고
    • Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis
    • R.R. Hajjar, F.E. Kaiser, and J.E. Morley Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis J Clin Endocrinol Metab 82 1997 3793 3796
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 3793-3796
    • Hajjar, R.R.1    Kaiser, F.E.2    Morley, J.E.3
  • 20
    • 0032754751 scopus 로고    scopus 로고
    • Hormone replacement in the ageing male?
    • M. Hermann, and P. Berger Hormone replacement in the ageing male? Exp Gerontol 34 1999 923 933
    • (1999) Exp Gerontol , vol.34 , pp. 923-933
    • Hermann, M.1    Berger, P.2
  • 21
    • 0035217823 scopus 로고    scopus 로고
    • Androgen replacement in the male: Recent studies
    • F.J. Hayes Androgen replacement in the male: recent studies Curr Opin Endocrinol Diabetes 8 2001 301 306
    • (2001) Curr Opin Endocrinol Diabetes , vol.8 , pp. 301-306
    • Hayes, F.J.1
  • 22
    • 0344406150 scopus 로고    scopus 로고
    • Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
    • J.C. Massengill, L. Sun, J.W. Moul, H. Wu, D.G. McLeod, and C. Amling Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy J Urol 169 2003 1670 1675
    • (2003) J Urol , vol.169 , pp. 1670-1675
    • Massengill, J.C.1    Sun, L.2    Moul, J.W.3    Wu, H.4    McLeod, D.G.5    Amling, C.6
  • 23
    • 0033950926 scopus 로고    scopus 로고
    • Is low serum free testosterone a marker for high grade prostate cancer?
    • M.A. Hoffman, W.C. DeWolf, and A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824 827
    • (2000) J Urol , vol.163 , pp. 824-827
    • Hoffman, M.A.1    Dewolf, W.C.2    Morgentaler, A.3
  • 24
    • 0036224481 scopus 로고    scopus 로고
    • The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis
    • S.S. Chen, K.K. Chen, A.T. Lin, Y.H. Chang, H.H. Wu, and L.S. Chang The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis BJU Int 89 2002 710 713
    • (2002) BJU Int , vol.89 , pp. 710-713
    • Chen, S.S.1    Chen, K.K.2    Lin, A.T.3    Chang, Y.H.4    Wu, H.H.5    Chang, L.S.6
  • 25
    • 0030690915 scopus 로고    scopus 로고
    • Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer
    • M. Ribeiro, P. Ruff, and G. Falkson Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer Am J Clin Oncol 20 1997 605 608
    • (1997) Am J Clin Oncol , vol.20 , pp. 605-608
    • Ribeiro, M.1    Ruff, P.2    Falkson, G.3
  • 27
    • 0029856354 scopus 로고    scopus 로고
    • Occult prostate cancer in men with low serum testosterone levels
    • A. Morgentaler, C.O. Bruning III, and W.C. DeWolf Occult prostate cancer in men with low serum testosterone levels JAMA 276 1996 1904 1906
    • (1996) JAMA , vol.276 , pp. 1904-1906
    • Morgentaler, A.1    Bruning III, C.O.2    Dewolf, W.C.3
  • 29
    • 0033304555 scopus 로고    scopus 로고
    • Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men
    • A.S. Dobs, A.W. Meikle, S. Arver, S.W. Sanders, K.E. Caramelli, and N.A. Mazer Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men J Clin Endocrinol Metab 84 1999 3469 3478
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 3469-3478
    • Dobs, A.S.1    Meikle, A.W.2    Arver, S.3    Sanders, S.W.4    Caramelli, K.E.5    Mazer, N.A.6
  • 32
    • 0034456450 scopus 로고    scopus 로고
    • Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group
    • C. Wang, R.S. Swedloff, A. Iranmanesh, A. Dobs, P.J. Snyder, and G. Cunningham Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group J Clin Endocrinol Metab 85 2000 2839 2853
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2839-2853
    • Wang, C.1    Swedloff, R.S.2    Iranmanesh, A.3    Dobs, A.4    Snyder, P.J.5    Cunningham, G.6
  • 33
    • 0035028887 scopus 로고    scopus 로고
    • Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels
    • A.M. Kenny, K.M. Prestwood, C.A. Gruman, K.M. Marcello, and L.G. Raisz Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels J Gerontol A Biol Sci Med Sci 56 2001 M266 M272
    • (2001) J Gerontol a Biol Sci Med Sci , vol.56
    • Kenny, A.M.1    Prestwood, K.M.2    Gruman, C.A.3    Marcello, K.M.4    Raisz, L.G.5
  • 34
    • 0242692553 scopus 로고    scopus 로고
    • Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: Results of 1 year of treatment in men with prostatic intraepithelial neoplasia
    • E.L. Rhoden, and A. Morgentaler Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia J Urol 170 2003 2348 2351
    • (2003) J Urol , vol.170 , pp. 2348-2351
    • Rhoden, E.L.1    Morgentaler, A.2
  • 35
    • 0036868435 scopus 로고    scopus 로고
    • Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement
    • R.E. Gerstenbluth, P.N. Maniam, E.W. Corty, and A.D. Seftel Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement J Androl 23 2002 922 926
    • (2002) J Androl , vol.23 , pp. 922-926
    • Gerstenbluth, R.E.1    Maniam, P.N.2    Corty, E.W.3    Seftel, A.D.4
  • 36
    • 0242390083 scopus 로고    scopus 로고
    • Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan
    • S. Bhasin, A.B. Singh, R.P. Mac, B. Carter, M.I. Lee, and G.R. Cunningham Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan J Androl 24 2003 299 311
    • (2003) J Androl , vol.24 , pp. 299-311
    • Bhasin, S.1    Singh, A.B.2    Mac, R.P.3    Carter, B.4    Lee, M.I.5    Cunningham, G.R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.